Tyrell J. Rivers

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Cerapedics, Inc. engaged in the provision of developing and commercializing novel osteobiologic products. It offers i-FACTOR Bone Graft, an advanced biologic that supported with level I evidence, and provides benefit ratio. The company was founded by Andrew J. Tofe and is headquartered in Westminster, CO.

Biohealth Innovation, Inc. sources and evaluates market-relevant bioheath intellectual properties, connects the IP with funding, and assists businesses in marketing and growth. It is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. The company was founded in 2011 and is headquartered in Rockville, MD.

VaxEquity Ltd. is a UK biotechnology company founded in 2020 by Professor Robin Shattock, the head of immunology of infection at Imperial College and Morningside. The company is based in Little Chesterford, UK. The British company is developing transformative RNA therapeutics and vaccines using its next-generation self-amplifying RNA platform called SARNA. The platform provides extended duration of protein expression, enabling lower doses to be used for vaccines and higher protein levels to be achieved for therapeutics. VaxEquity is pioneering a next-generation approach by modifying its SARNA to modulate the innate immune response and thereby overcoming current limitations. The flexibility of the company's platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale.